Alimentary Pharmacology & Therapeutics

Helicobacter pylori and reflux disease
pp. 297-305(9)
Authors: Sharma, P.; Vakil, N.

Nutrition and adult inflammatory bowel disease
pp. 307-320(14)
Authors: Goh, J.; O'Morain, C. A.

NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors
pp. 321-332(12)
Authors: Micklewright, R.; Lane, S.; Linley, W.; McQuade, C.; Thompson, F.; Maskrey, N.

Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results
pp. 333-341(9)
Authors: Lauritsen, K.; Devière, J.; Bigard, M.-A.; Bayerdörffer, E.; Mózsik, G.; Murray, F.; Kristjánsdóttir, S.; Savarino, V.; Vetvik, K.; De Freitas, D.; Orive, V.; Rodrigo, L.; Fried, M.; Morris, J.; Schneider, H.; Eklund, S.; Larkö, A.

A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years
pp. 343-351(9)
Authors: Thjodleifsson, B.; Rindi, G.; Fiocca, R.; Humphries, T. J.; Morocutti, A.; Miller, N.; Bardhan, K. D.

Circadian pattern of intragastric acidity in patients with non-erosive reflux disease (NERD)
pp. 353-359(7)
Authors: Zentilin, P.; Dulbecco, P.; Bilardi, C.; Gambaro, C.; Iiritano, E.; Biagini, R.; Mela, G. S.; Tessieri, L.; Mele, M. R.; Mansi, C.; Pandolfo, N.; Vigneri, S.; Savarino, V.

Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects
pp. 361-367(7)
Authors: Freston, J. W.; Chiu, Y.-L.; Mulford, D. J.; Ballard II, E. D.

Symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy-negative patients with non-cardiac chest pain
pp. 369-377(9)
Authors: Xia, H. H. X.; Lai, K. C.; Lam, S. K.; Hu, W. H. C.; Wong, N. Y. H.; Hui, W. M.; Lau, C. P.; Chen, W. H.; Chan, C. K.; Wong, W. M.; Wong, B. C. Y.

Cyclo-oxygenase-2 expression in Barrett's oesophageal carcinogenesis: an immunohistochemical study
pp. 379-386(8)
Authors: Cheong, E.; Igali, L.; Harvey, I.; Mole, M.; Lund, E.; Johnson, I. T.; Rhodes, M.

Response of fistulating Crohn's disease to infliximab treatment assessed by magnetic resonance imaging
pp. 387-393(7)
Authors: Bell, S. J.; Halligan, S.; Windsor, A. C. J.; Williams, A. B.; Wiesel, P.; Kamm, M. A.

Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation
pp. 395-402(8)
Authors: Brunner, M.; Assandri, R.; Kletter, K.; Tschurlovits, M.; Corrado, M. E.; Villa, R.; Eichler, H. G.; Müller, M.

Pharmacokinetics of budesonide controlled-release capsules when taken with omeprazole
pp. 403-408(6)
Authors: Edsbäcker, S.; Larsson, P.; Bergstrand, M.

Patients with refractory Crohn's disease or ulcerative colitis respond to dehydroepiandrosterone: a pilot study
pp. 409-414(6)
Authors: Andus, T.; Klebl, F.; Rogler, G.; Bregenzer, N.; Schölmerich, J.; Straub, R. H.

Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study
pp. 415-420(6)
Authors: O'Morain, C.; Borody, T.; Farley, A.; De Boer, W. A.; Dallaire, C.; Schuman, R.; Piotrowski, J.; Fallone, C. A.; Tytgat, G.; Mégraud, F.; Spénard, J.

Helicobacter pylori strains and histologically-related lesions affect the outcome of triple eradication therapy: a study from southern Italy
pp. 421-428(8)
Authors: Russo, F.; Berloco, P.; Cuomo, R.; Caruso, M. L.; Di Matteo, G.; Giorgio, P.; De Francesco, V.; Di Leo, A.; Ierardi, E.

Effect of frequent consumption of a Lactobacillus casei-containing milk drink in Helicobacter pylori-colonized subjects
pp. 429-435(7)
Authors: Cats, A.; Kuipers, E. J.; Bosschaert, M. A. R.; Pot, R. G. J.; Vandenbroucke-Grauls, C. M. J. E.; Kusters, J. G.

Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience
pp. 437-444(8)
Authors: Garland, J.; Buscombe, J. R.; Bouvier, C.; Bouloux, P.; Chapman, M. H.; Chow, A. C.; Reynolds, N.; Caplin, M. E.

Effect of peppermint oil and caraway oil on gastrointestinal motility in healthy volunteers: a pharmacodynamic study using simultaneous determination of gastric and gall-bladder emptying and orocaecal transit time
pp. 445-451(7)
Authors: Goerg, K. J.; Spilker, TH.

Helicobacter DNA in bile: correlation with hepato-biliary diseases
pp. 453-458(6)
Authors: Fallone, C. A.; Tran, S.; Semret, M.; Discepola, F.; Behr, M.; Barkun, A. N.

Oral desensitizing treatment in food allergy: clinical and immunological results
pp. 459-465(7)
Authors: Patriarca, G.; Nucera, E.; Roncallo, C.; Pollastrini, E.; Bartolozzi, F.; De Pasquale, T.; Buonomo, A.; Gasbarrini, G.; Di Campli, C.; Schiavino, D.

A prospective, comparative study of the para-aminobenzoic acid test and faecal elastase 1 in the assessment of exocrine pancreatic function
pp. 467-471(5)
Authors: Sonwalkar, S. A.; Holbrook, I. B.; Phillips, I.; Kelly, S. M.

Second harmonic imaging improves trans-abdominal ultrasound detection of biliary sludge in `idiopathic' pancreatitis
pp. 473-477(5)
Authors: Ierardi, E.; Muscatiello, N.; Nacchiero, M.; Gentile, M.; Margiotta, M.; Marangi, S.; De Francesco, V.; Francavilla, R.; Barone, M.; Faleo, D.; Panella, C.; Francavilla, A.; Cuomo, R.

Methotrexate in ulcerative colitis
pp. 479-480(2)
Authors: Siveke, J. T.; Folwaczny, C.